Annovis Bio, Inc. ANVS
We take great care to ensure that the data presented and summarized in this overview for Annovis Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANVS
View all-
Vanguard Group Inc Valley Forge, PA358KShares$2.87 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA250KShares$2.01 Million0.01% of portfolio
-
Black Rock Inc. New York, NY97.6KShares$783,9600.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA72.6KShares$582,9940.0% of portfolio
-
Geode Capital Management, LLC Boston, MA70.8KShares$568,4510.0% of portfolio
-
Wescott Financial Advisory Group, LLC41.6KShares$334,1040.07% of portfolio
-
Redmond Asset Management, LLC Henrico, VA36.2KShares$290,3400.14% of portfolio
-
Sterling Investment Advisors, Ltd.34.4KShares$276,0230.12% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX33.6KShares$269,8080.01% of portfolio
-
Modera Wealth Management, LLC30.5KShares$245,0190.01% of portfolio
Latest Institutional Activity in ANVS
Top Purchases
Top Sells
About ANVS
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Insider Transactions at ANVS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 20
2023
|
Henry Hagopian Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
824
+31.12%
|
$4,944
$6.07 P/Share
|
|
Nov 20
2023
|
Maria Luisa Maccecchini President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
41,186
+3.61%
|
$247,116
$6.07 P/Share
|
|
Nov 20
2023
|
Mark K. White Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+3.17%
|
$12,000
$6.07 P/Share
|
|
Nov 20
2023
|
Michael B Hoffman Director |
BUY
Grant, award, or other acquisition
|
Indirect |
164,745
+42.35%
|
$988,470
$6.07 P/Share
|
|
Nov 20
2023
|
Reid Mc Carthy Director |
BUY
Grant, award, or other acquisition
|
Direct |
824
+9.2%
|
$4,944
$6.07 P/Share
|
|
Nov 20
2023
|
Claudine Bruck Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+11.67%
|
$6,000
$6.07 P/Share
|
|
Apr 24
2023
|
Maria Luisa Maccecchini President and CEO |
SELL
Bona fide gift
|
Direct |
3,000
-0.28%
|
-
|
|
Apr 07
2023
|
Claudine Bruck Director |
BUY
Grant, award, or other acquisition
|
Direct |
500
+7.08%
|
$6,000
$12.61 P/Share
|
|
Apr 07
2023
|
Mark K. White Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+4.82%
|
$36,000
$12.61 P/Share
|
|
Apr 07
2023
|
Reid Mc Carthy Director |
BUY
Grant, award, or other acquisition
|
Direct |
476
+6.12%
|
$5,712
$12.61 P/Share
|
|
Apr 07
2023
|
Michael B Hoffman Director |
BUY
Grant, award, or other acquisition
|
Indirect |
59,477
+50.0%
|
$713,724
$12.61 P/Share
|
|
Apr 07
2023
|
Henry Hagopian Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+50.0%
|
$12,000
$12.61 P/Share
|
|
Apr 07
2023
|
Maria Luisa Maccecchini President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+1.85%
|
$240,000
$12.61 P/Share
|
|
Feb 06
2023
|
Maria Luisa Maccecchini President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
52,755
+4.83%
|
$0
$0.14 P/Share
|
|
Jan 14
2022
|
Maria Luisa Maccecchini President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,959
+3.23%
|
$0
$0.14 P/Share
|
|
Jan 04
2022
|
Michael B Hoffman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,748
-0.24%
|
$128,212
$19.78 P/Share
|
|
Jan 04
2022
|
Michael B Hoffman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
37,142
+1.29%
|
$74,284
$2.32 P/Share
|
|
Oct 12
2021
|
Mark K. White Director |
BUY
Open market or private purchase
|
Direct |
5,000
+8.17%
|
$135,000
$27.4 P/Share
|
|
Oct 11
2021
|
Maria Luisa Maccecchini President and CEO |
BUY
Open market or private purchase
|
Direct |
18,000
+1.81%
|
$486,000
$27.61 P/Share
|
|
Oct 11
2021
|
Claudine Bruck Director |
BUY
Open market or private purchase
|
Direct |
181
+2.9%
|
$4,887
$27.66 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 211K shares |
|---|